These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34121634)

  • 21. Prevalence of hepatitis C virus among fatal drug overdoses in Tennessee: an analysis using 2019-2020 Tennessee State Unintentional Drug Overdose Reporting System Data.
    Korona-Bailey J; Riley Saint S; Sizemore L; Wingate H; Shoup P; Hawes A; Mukhopadhyay S
    Ann Epidemiol; 2023 Apr; 80():1-8. PubMed ID: 36758846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of co-occurring substance use in individuals with opioid use disorder.
    Mahoney JJ; Winstanley EL; Lander LR; Berry JH; Marshalek PJ; Haut MW; Marton JL; Kimble WD; Armistead M; Wen S; Cai Y; Hodder SL
    Addict Behav; 2021 Mar; 114():106752. PubMed ID: 33348147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
    Walley AY; Lodi S; Li Y; Bernson D; Babakhanlou-Chase H; Land T; Larochelle MR
    Addiction; 2020 Aug; 115(8):1496-1508. PubMed ID: 32096908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
    O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
    Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
    Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
    Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014.
    Zibbell JE; Asher AK; Patel RC; Kupronis B; Iqbal K; Ward JW; Holtzman D
    Am J Public Health; 2018 Feb; 108(2):175-181. PubMed ID: 29267061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial.
    Pericot-Valverde I; Heo M; Akiyama MJ; Norton BL; Agyemang L; Niu J; Litwin AH
    BMC Infect Dis; 2020 Dec; 20(1):928. PubMed ID: 33276738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polysubstance use trends and variability among individuals with opioid use disorder in rural versus urban settings.
    Ellis MS; Kasper ZA; Cicero TJ
    Prev Med; 2021 Nov; 152(Pt 2):106729. PubMed ID: 34293380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion.
    Wilton J; Wong S; Purssell R; Abdia Y; Chong M; Karim ME; MacInnes A; Bartlett SR; Balshaw RF; Gomes T; Yu A; Alvarez M; Dart RC; Krajden M; Buxton JA; Janjua NZ
    JAMA Netw Open; 2022 Jan; 5(1):e2143050. PubMed ID: 35019983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection.
    Eller AJ; DiDomizio EE; Madden LM; Oliva JD; Altice FL; Johnson KA
    Ann Med; 2022 Dec; 54(1):1714-1724. PubMed ID: 35775786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.
    Ochalek TA; Heil SH; Higgins ST; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2018 Sep; 190():224-228. PubMed ID: 30056321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of hepatitis C screening within a pharmacist-managed medication-assisted therapy opioid use disorder protocol program.
    Llayton CK; Harlow CP; Burris JN; Rhodes J
    J Am Pharm Assoc (2003); 2020; 60(6):e307-e311. PubMed ID: 32527703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States.
    Boesecke C; Rockstroh JK
    Hepatology; 2019 Apr; 69(4):1832-1834. PubMed ID: 30251386
    [No Abstract]   [Full Text] [Related]  

  • 35. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
    Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection.
    Williams N; Bossert N; Chen Y; Jaanimägi U; Markatou M; Talal AH
    J Subst Abuse Treat; 2019 Jul; 102():33-39. PubMed ID: 31202286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
    Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
    Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: A retrospective cohort study.
    Krans EE; Zickmund SL; Rustgi VK; Park SY; Dunn SL; Schwarz EB
    Subst Abus; 2016; 37(1):88-95. PubMed ID: 26569631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex-Specific Risk Factors and Health Disparity Among Hepatitis C Positive Patients Receiving Pharmacotherapy for Opioid Use Disorder: Findings From a Propensity Matched Analysis.
    Dennis BB; Martin LJ; Naji L; Akhtar D; Cholankeril G; Kim D; Sanger N; Hillmer A; Chawar C; D'Elia A; Panesar B; Worster A; Marsh DC; O'Shea T; Bawor M; Thabane L; Samaan Z; Ahmed A
    J Addict Med; 2022 Jul-Aug 01; 16(4):e248-e256. PubMed ID: 34799492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.